The Food and Drug Administration (FDA) has approved a tablet formulation of Livmarli ® (maralixibat).

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ...

Mirum announced the FDA approved a new tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille ...

The investment significantly expands Ashland’s pharmaceutical footprint in the region and capabilities to meet increasing market demand for coated tablets in Latin America and Brazil.